Lung Cancer Update
by Dr. Neil Love
Is this your podcast?Insights from recent episode analysis
Audience Interest
Podcast Focus
Publishing Consistency
Platform Reach
Insights are generated by CastFox AI using publicly available data, episode content, and proprietary models.
Most discussed topics
Brands & references
Total monthly reach
Estimated from 2 chart positions in 2 markets.
By chart position
- 🇮🇪IE · Science#4510K to 30K
- 🇩🇰DK · Science#167500 to 3K
- Per-Episode Audience
Est. listeners per new episode within ~30 days
5.3K to 17K🎙 Weekly cadence·48 episodes·Last published 1mo ago - Monthly Reach
Unique listeners across all episodes (30 days)
11K to 33K🇮🇪91%🇩🇰9% - Active Followers
Loyal subscribers who consistently listen
3.1K to 9.9K
Market Insights
Platform Distribution
Reach across major podcast platforms, updated hourly
Total Followers
—
Total Plays
—
Total Reviews
—
* Data sourced directly from platform APIs and aggregated hourly across all major podcast directories.
On the show
From 17 epsHosts
Recent guests
Recent episodes
HER2-Altered Non-Small Cell Lung Cancer — Rapid Case Review
Jul 14, 2026
27m 32s
Nonmetastatic Non-Small Cell Lung Cancer — An Interview with Dr Jamie E Chaft
Jul 11, 2026
59m 55s
For Oncology Nurses: Strategies to Safely and Effectively Implement Antibody-Drug Conjugates — Proceedings from the 2026 Annual ONS Congress
Jul 8, 2026
1h 28m 54s
Targeted Therapies for Non-Small Cell Lung Cancer — Fifth Annual National General Medical Oncology Summit
Jun 30, 2026
50m 08s
EGFR-Mutated Non-Small Cell Lung Cancer — Fifth Annual National General Medical Oncology Summit
Jun 27, 2026
51m 09s
Social Links & Contact
Official channels & resources
Official Website
Login
RSS Feed
Login
| Date | Episode | Topics | Guests | Brands | Places | Keywords | Sponsor | Length | |
|---|---|---|---|---|---|---|---|---|---|
| 7/14/26 | HER2-altered lung cancernon-small cell lung cancer+4 | Dr Mark JengDr Joshua K Sabari | zongertinibPD-L1+2 | — | HER2non-small cell lung cancer+5 | — | 27m 32s | ||
| 7/11/26 | nonmetastatic non-small cell lung cancerimmunotherapy+4 | Dr Jamie E Chaft | NeoADAURAPD-L1+1 | — | lung cancerimmunotherapy+6 | — | 59m 55s | ||
| 7/8/26 | Antibody-Drug ConjugatesBreast Cancer+4 | Ms Courtney ArnMs Jamie Carroll+3 | ONS CongressAntibody-Drug Conjugates+2 | — | Antibody-Drug ConjugatesHER2-Targeted ADCs+6 | — | 1h 28m 54s | ||
| 6/30/26 | Targeted TherapiesNon-Small Cell Lung Cancer+4 | Dr Lyudmila BazhenovaDr Corey J Langer | National General Medical Oncology SummitHER2+3 | — | lung cancertargeted therapies+7 | — | 50m 08s | ||
| 6/27/26 | EGFR-Mutated Non-Small Cell Lung CancerMetastatic NSCLC+4 | Dr Jonathan GoldmanDr Zofia Piotrowska | National General Medical Oncology SummitEGFR-Mutated Non-Small Cell Lung Cancer | — | EGFRNon-Small Cell Lung Cancer+5 | — | 51m 09s | ||
| 6/18/26 | small cell lung cancerchemoimmunotherapy+4 | Prof Martin Reck | lurbinectedinatezolizumab+2 | — | small cell lung cancerchemoimmunotherapy+5 | — | 40m 45s | ||
| 6/9/26 | small cell lung cancerclinical trials+3 | Dr Christine L HannDr Jacob Sands | Johns Hopkins University School of MedicineDana-Farber Cancer Institute | Baltimore, MarylandBoston, Massachusetts | small cell lung cancerclinical trials+3 | — | 58m 47s | ||
| 4/27/26 | EGFR mutationnon-small cell lung cancer+3 | Dr Suresh S RamalingamDr Helena Yu | EGFRnon-small cell lung cancer | — | EGFR mutationnon-small cell lung cancer+3 | — | 57m 26s | ||
| 4/17/26 | lung cancercirculating tumor DNA+3 | Dr Natalie Vokes | The University of Texas MD Anderson Cancer CenterLung Cancer Update | — | lung cancercirculating tumor DNA+3 | — | 27m 12s | ||
| 2/27/26 | lung cancersmall cell lung cancer+3 | Dr Hossein BorghaeiDr Anne Chiang | Fox Chase Cancer CenterYale Cancer Center | Philadelphia, PennsylvaniaNew Haven, Connecticut | extensive-stage small cell lung cancerfirst-line management+3 | — | 59m 42s | ||
| 12/17/25 | small cell lung cancerfirst-line therapy+3 | Dr Luis Paz-AresDr Shields | Spanish National Oncology Research CenterIndiana University School of Medicine | — | extensive-stagesmall cell lung cancer+4 | — | 57m 46s | ||
| 12/12/25 | lung cancertreatment landscape+3 | Dr Justin F GainorDr Corey J Langer+1 | American Oncology Network | — | lung cancertreatment+3 | — | 1h 43m 11s | ||
| 12/10/25 | HER2-altered non-small cell lung cancertreatment strategies+3 | Dr John Heymach | The University of Texas MD Anderson Cancer CenterLung Cancer Update | — | HER2non-small cell lung cancer+3 | — | 1h 05m 13s | ||
| 11/10/25 | lung cancerantibody-drug conjugates+3 | Dr Aaron Lisberg | TROP2-directed antibody-drug conjugatesUniversity of California, Los Angeles | non-small cell lung cancer | lung cancerTROP2+3 | — | 21m 21s | ||
| 10/20/25 | lung cancerTROP2+3 | Dr Aaron Lisberg | TROP2-directed antibody-drug conjugatesUniversity of California, Los Angeles | non-small cell lung cancer | lung cancerTROP2+3 | — | 24m 47s | ||
| 9/14/25 | lung cancerTROP2-directed antibody-drug conjugates+3 | Dr Jacob Sands | Dana-Farber Cancer Institute | Boston, Massachusetts | lung cancerTROP2+4 | — | 23m 19s | ||
| 8/22/25 | small cell lung cancertherapies+3 | Dr Stephen V LiuDr Charles Rudin | Georgetown University HospitalMemorial Sloan Kettering Cancer Center | Washington, DCNew York | small cell lung cancertherapies+3 | — | 58m 18s |
Showing 17 of 17
Pitch Fit is a Pro feature
See how bookable this show is for guests, which brands already advertise, the per-episode ad value, and the best-fit guest and sponsor profile. The numbers are blurred on the free plan.
How readily this show books outside guests like you.
How proven this show is for host-read sponsorships.
For Guests
ProFor Advertisers
ProUpgrade to Pro to unlock guest cadence, sponsor categories, fit scores, and per-episode ad value for this show.
Chart history for Lung Cancer Update
Peaked at #45 in Ireland, currently #45 in Ireland.
| Market | Genre | Peak | Current | Trend |
|---|---|---|---|---|
| Ireland | — | #45 | #45 | — |
| Denmark | — | #167 | #167 | — |
Chart Positions
2 placements across 2 markets.
Chart Positions
2 placements across 2 markets.